Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Bordi

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Translational Lung Cancer Research|February 3, 2017
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistanceRoberta Minari, Paola Bordi, Marcello Tiseo
The New England Journal of Medicine|May 5, 2016
Crizotinib Resensitization by Compound MutationPaola Bordi, Marzia Del Re, Marcello Tiseo
BMC Cancer|August 14, 2016
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case reportPaola Bordi, Marcello Tiseo, Giorgio Baldari, et al.
Translational Lung Cancer Research|December 3, 2015
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerPaola Bordi, Marzia Del Re, Romano Danesi, et al.
Drug Design, Development and Therapy|September 22, 2018
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectivesFrancesco Facchinetti, Paola Bordi, Alessandro Leonetti, et al.
Tumori|February 24, 2015
Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADHPaola Bordi, Marcello Tiseo, Sebastiano Buti, et al.
Current Drug Targets|February 14, 2018
Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature ReviewFrancesco Facchinetti, Paola Bordi, Paola Bini, et al.
Tumori|February 8, 2013
Narrative literature and cancer: improving the doctor-patient relationshipEnrico Aitini, Paola Bordi, Chiara Dell'agnola, et al.
Clinical Lung Cancer|November 28, 2017
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the LiteratureBenedetta Pellegrino, Francesco Facchinetti, Paola Bordi, et al.
Tumori|March 29, 2014
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case reportPaola Bordi, Marcello Tiseo, Beatrice Bortesi, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Translational Lung Cancer Research|February 3, 2017
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistanceRoberta Minari, Paola Bordi, Marcello Tiseo
The New England Journal of Medicine|May 5, 2016
Crizotinib Resensitization by Compound MutationPaola Bordi, Marzia Del Re, Marcello Tiseo
BMC Cancer|August 14, 2016
Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case reportPaola Bordi, Marcello Tiseo, Giorgio Baldari, et al.
Translational Lung Cancer Research|December 3, 2015
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerPaola Bordi, Marzia Del Re, Romano Danesi, et al.
Drug Design, Development and Therapy|September 22, 2018
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectivesFrancesco Facchinetti, Paola Bordi, Alessandro Leonetti, et al.
Tumori|February 24, 2015
Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADHPaola Bordi, Marcello Tiseo, Sebastiano Buti, et al.
Current Drug Targets|February 14, 2018
Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature ReviewFrancesco Facchinetti, Paola Bordi, Paola Bini, et al.
Tumori|February 8, 2013
Narrative literature and cancer: improving the doctor-patient relationshipEnrico Aitini, Paola Bordi, Chiara Dell'agnola, et al.
Clinical Lung Cancer|November 28, 2017
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the LiteratureBenedetta Pellegrino, Francesco Facchinetti, Paola Bordi, et al.
Tumori|March 29, 2014
Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case reportPaola Bordi, Marcello Tiseo, Beatrice Bortesi, et al.
Pageof 7